Avellino and Sugentech Announce Strategic Collaboration
Partnership Focused In Short Term On COVID-19 Genetic Diagnostics and Solutions, Long Term Collaboration On Partner Diagnostics and Therapeutics
Sugentech Incorporated is a company headquartered in Daejeon in the Republic of Korea (South Korea). The company is focused on the production and sale of in-vitro diagnostic test reagents. Sugentech is also involved in the manufacturing and sale of in-vitro diagnostic test reagents, point-of-care testing (POCT) products, folic acid products under the name of SOLGAR, as well as molecular diagnostic reagents. The in-vitro diagnostic test reagents are for personal use and are sold under the name SUREARLY. The POCT products are for professional use and are sold under the name INCLIX. In addition, the Company is engaged in therapeutic drug monitoring, as well as drug analysis method development.
View source version on businesswire.com:
Avellino Lab USA, Inc. is a global leader in gene therapy and molecular diagnostics and is at the forefront of precision medicine for eye care. The company is pioneering CRISPR gene editing to manage and potentially cure inherited diseases. Beyond the Avellino CoV2 test, Avellino recently launched AvaGen, the world’s first DNA test to confirm the presence of genetic indicators that are positively associated with corneal dystrophies and keratoconus genetic risk factors. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan, China, and the UK.